Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers.
The mass balance and pharmacokinetics of telavancin, a semisynthetic lipoglycopeptide antimicrobial agent, were characterized in an open-label, phase 1 study of six healthy male subjects. After a single 1-h intravenous infusion of 10 mg/kg [14C]telavancin (0.68 microCi/kg), blood, urine, and feces were collected at regular intervals up to 216 h postdose. Whole blood, plasma, urine, and fecal samples were assayed for total radioactivity using scintillation counting; plasma and urine were also assayed for parent drug and metabolites using liquid chromatography with tandem mass spectrometry. The concentration-time profiles for telavancin and total radioactivity in plasma were comparable from 0 to 24 h after the study drug administration. Telavancin accounted for >95% and 83% of total radioactivity in plasma at 12 h and 24 h, respectively. By 216 h, approximately 76% of the total administered dose was recovered in urine while only 1% was collected in feces. Unchanged telavancin accounted for most (83%) of the eliminated dose. Telavancin metabolite THRX-651540 along with two other hydroxylated metabolites (designated M1 and M2) accounted for the remaining radioactivity recovered from urine. The mean concentrations of total radioactivity in whole blood were lower than the concentration observed in plasma, and mean concentrations of THRX-651540 in plasma were minimal relative to mean plasma telavancin concentrations. These observations demonstrate that most of an administered telavancin dose is eliminated unchanged via the kidneys. Intravenous telavancin at 10 mg/kg was well tolerated by all subjects.
Shaw
Jeng-Pyng
JP
Department of Drug Metabolism and Pharmacokinetics, Theravance, Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA. jp.shaw@bioduro.com.
Cheong
Jonathan
J
Goldberg
Michael R
MR
Kitt
Michael M
MM
D000617:Aminoglycosides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D002250:Carbon Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D002853:Chromatography, Liquid; D005243:Feces / Q000737:chemistry; D006801:Humans; D007262:Infusions, Intravenous; D000077427:Lipoglycopeptides; D008297:Male; D053719:Tandem Mass Spectrometry; D016896:Treatment Outcome
D000617:Aminoglycosides; D000890:Anti-Infective Agents; D002250:Carbon Radioisotopes; D000077427:Lipoglycopeptides; C487637:telavancin